About CyCa Oncosolutions
CyCa Oncosolutions is a Healthcare company based in Delaware City (United States) founded in 2017 by Taiyyaba Kausar and Saikh Fazlul Haque Krishnan. Proprietary drug delivery technology for cancer treatment is developed. Its Indian entity Cygenica Private Limited reported revenue of ₹1.43 Cr. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Similar companies include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed similar companies have raised funding.
Company details
CyCa OncoSolutions was founded in 2017 in Delaware City, United States, and operates in the life sciences sector. Drug delivery technology is provided to industry partners through a proprietary non-endocytic cell entry mechanism. Higher cellular uptake is achieved with lower dosages and fewer side effects, according to company claims. Primary application is targeted toward cancer cells.
- Headquarters Delaware City, United States
- Founders Taiyyaba Kausar, Saikh Fazlul Haque Krishnan
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cycaonco.com
- Social LinkedIn X
- Legal Name Cygenica Private Limited
- Date of Incorporation 28 Feb, 2017
- Jurisdiction Baleshwar, Odisha, India
- Indian entity revenue₹1.43 Cr
FY 2025 · +22% YoY
- Indian entity net profit₹13.2 Lakh
FY 2025 · 9% margin
- Indian entity EBITDA₹27.6 Lakh
FY 2025 · 19% margin
Associated legal entities of CyCa Oncosolutions
CyCa Oncosolutions operates through Cygenica Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Cygenica Private Limited CIN U74999OR2017PTC026637 | Active | 28 Feb 2017 | Baleshwar, Odisha | ₹1.4 Cr | 2 | View details |
Board of directors of Cygenica Private Limited (CyCa Oncosolutions)
Cygenica Private Limited is the primary company behind CyCa Oncosolutions. The board of Cygenica Private Limited currently have 2 directors; the longest-serving is Saikh Fazlul Haque Krishnan, appointed in 2017. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Saikh Fazlul Haque Krishnan DIN 07751477 | Director | 28 Feb 2017 | 9 yrs 8 mo | Cygenica Private Limited |
| Nusrat Jahan Mobassarah Sanghamitra DIN 07751476 | Managing Director | 28 Feb 2017 | 9 yrs 8 mo | Cygenica Private Limited |
People of CyCa Oncosolutions
2 people are tracked at CyCa Oncosolutions (2 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder | Leadership | |
| Founder | Leadership |
Complete people profiles for CyCa Oncosolutions
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of CyCa Oncosolutions
Figures of Cygenica Private Limited, the primary company behind CyCa Oncosolutions, for FY 2025. Revenue was ₹1.43 Cr (+22% year on year). Net profit was ₹13.2 Lakh (9% margin). EBITDA was ₹27.6 Lakh (19% margin). Revenue has grown at a compounded annual rate of 0% over three years and +24% over five years.
- ₹1.43 CrRevenue · FY 2025 · +22% YoY
- ₹13.2 LakhNet profit · 9% margin
- ₹27.6 LakhEBITDA · 19% margin
- ₹1 LakhPaid-up capital
- 0%Revenue CAGR, 3 years
- +24%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Cygenica Private Limited are on its company page.
Detailed financial statements for CyCa Oncosolutions
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to CyCa Oncosolutions
CyCa Oncosolutions has 3 listed similar companies in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed similar companies of CyCa Oncosolutions
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as CyCa Oncosolutions (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cyca Oncosolutions
Complete news archive for CyCa Oncosolutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CyCa Oncosolutions
CyCa Oncosolutions was founded in 2017.
CyCa Oncosolutions is headquartered in Delaware City, United States. It is registered at Delaware City, Delaware, United States.
The primary company behind CyCa Oncosolutions, Cygenica Private Limited, reported revenue of ₹1.43 Cr for FY 2025, up 22% year on year.
CyCa OncoSolutions was founded in 2017 in Delaware City, United States, and operates in the life sciences sector. Drug delivery technology is provided to industry partners through a proprietary non-endocytic cell entry mechanism. Higher cellular uptake is achieved with lower dosages and fewer side effects, according to company claims. Primary application is targeted toward cancer cells.
CyCa Oncosolutions's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
CyCa Oncosolutions operates through Cygenica Private Limited.
The legal entities of CyCa Oncosolutions currently have 2 directors, including Saikh Fazlul Haque Krishnan, Nusrat Jahan Mobassarah Sanghamitra.